We are live on ! Find out more
CHRS icon

Coherus Oncology
CHRS

163 hedge funds and large institutions have $536M invested in Coherus Oncology in 2023 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 46 increasing their positions, 65 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

180% more call options, than puts

Call options by funds: $1.04M | Put options by funds: $372K

17% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 18

1% more funds holding

Funds holding: 161 → 163 (+2)

2.57% less ownership

Funds ownership: 101.09% → 98.52% (-2.6%)

14% less capital invested

Capital invested by funds: $623M → $536M (-$86.2M)

29% less repeat investments, than reductions

Existing positions increased: 46 | Existing positions reduced: 65

Holders
163
Holders Change
+2
Holders Change %
+1.24%
% of All Funds
2.6%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
21
Increased
46
Reduced
65
Closed
18
Calls
$1.04M
Puts
$372K
Net Calls
+$669K
Net Calls Change
+$750K

Top Buyers

Rank Fund Capital Flow
1
Marshall Wace
Marshall Wace
United Kingdom
+$4.45M
2
PAMS
Pictet Asset Management (Switzerland)
Switzerland
+$4.22M
3
BlackRock
BlackRock
New York
+$2.45M
4
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$2.16M
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$1.47M

Top Sellers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
-$5.34M
2
JP Morgan Chase
JP Morgan Chase
New York
-$4.05M
3
Ameriprise
Ameriprise
Minnesota
-$3.56M
4
Millennium Management
Millennium Management
New York
-$2.52M
5
N
Nuveen
North Carolina
-$2.23M
Name Holding Trade Value Shares
Change 		Change in
Stake
Jacobs Levy Equity Management
26
Jacobs Levy Equity Management
New Jersey
$3.55M -$1.89M -243,897 -32%
Morgan Stanley
27
Morgan Stanley
New York
$3.48M -$1.59M -204,647 -29%
Charles Schwab
28
Charles Schwab
California
$3.46M -$12K -1,547 -0.3%
Macquarie Group
29
Macquarie Group
Australia
$2.94M – – –
CS
30
Credit Suisse
Switzerland
$2.81M -$219K -28,256 -6%
Principal Financial Group
31
Principal Financial Group
Iowa
$2.75M -$70.9K -9,135 -2%
Rafferty Asset Management
32
Rafferty Asset Management
New York
$2.74M -$534K -68,813 -15%
Susquehanna International Group
33
Susquehanna International Group
Pennsylvania
$2.59M +$1.47M +189,072 +100%
Lazard Asset Management
34
Lazard Asset Management
New York
$2.58M +$463K +59,611 +19%
BNP Paribas Financial Markets
35
BNP Paribas Financial Markets
France
$2.56M +$447K +57,566 +18%
AA
36
AlphaCentric Advisors
Puerto Rico
$2.42M +$1.3M +167,000 +89%
Invesco
37
Invesco
Georgia
$1.93M -$463K -59,708 -17%
Millennium Management
38
Millennium Management
New York
$1.49M -$2.52M -324,147 -60%
Balyasny Asset Management
39
Balyasny Asset Management
Illinois
$1.48M -$612K -78,832 -27%
RhumbLine Advisers
40
RhumbLine Advisers
Massachusetts
$1.41M +$78.8K +10,159 +5%
UBS Group
41
UBS Group
Switzerland
$1.41M -$778K -100,237 -33%
KCM
42
Kennedy Capital Management
Missouri
$1.39M – – –
CM
43
CM Management
Florida
$1.37M +$194K +25,000 +14%
TCM
44
Tang Capital Management
California
$1.37M +$653K +84,100 +73%
Barclays
45
Barclays
United Kingdom
$1.29M -$858K -110,490 -37%
N
46
Nuveen
North Carolina
$1.2M -$2.23M -286,867 -62%
BCC
47
Bridge City Capital
Oregon
$1.14M -$4.94K -636 -0.4%
PFC
48
Phocas Financial Corp
California
$1.12M +$1.27M +163,140 New
CSS
49
Cubist Systematic Strategies
Connecticut
$1.09M -$338K -43,488 -21%
State of Wisconsin Investment Board
50
State of Wisconsin Investment Board
Wisconsin
$1.09M +$366K +47,128 +42%
1
2
3 4 5

CHRS Hedge Fund Activity: Q1 2023 in Review

163 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Coherus Oncology (CHRS) for Q1 2023, worth a combined $536M — down 14% from $623M a quarter earlier.

Buyers outnumbered sellers: 21 funds opened new CHRS positions and 18 closed out — a net gain of 3 holders — while 46 added to existing stakes and 65 trimmed.

The largest buyer was Marshall Wace, opening a new position worth an estimated $4.45M. The largest seller was State Street, cutting an estimated $5.34M.

  • 163 institutional investors held Coherus Oncology (CHRS) as of Q1 2023, up from 161 in Q4 2022.
  • Funds reported $536M of Coherus Oncology stock for Q1 2023, down 14% quarter-over-quarter.
  • 21 funds opened new Coherus Oncology positions in Q1 2023 and 18 closed out, a net change of +3 holders.
  • The largest Coherus Oncology buyer in Q1 2023 was Marshall Wace, an estimated $4.45M added.
  • The largest Coherus Oncology seller in Q1 2023 was State Street, an estimated $5.34M sold.

Based on aggregated 13F filings for Q1 2023.